Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Inclusion Criteria: 1. Female patients aged 18-70 years; 2. Histopathologically confirmed HER2 positive breast cancer; 3. Patients were diagnosed with stage II-III breast cancer; 4. At least one measurable target lesion according to RECIST V1.1; 5. ECOG performance status score of 0 to 1; 6. Life expectancy ≥12 weeks; 7. Adequate bone marrow reserve and organ system function reserve; 8. Participants should be able and willing to comply with the study protocol requirement; Exclusion Criteria: 1. Breast cancer not histologically confirmed; 2. Known inherited or acquired bleeding and thrombotic tendencies; 3. Known allergy or contraindication to the study drug and its excipients; 4. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); 5. Concurrent receipt of any other form of anti-cancer therapy; 6. History of a second primary malignancy, except for adequately treated skin cancer; 7. Participation in other drug clinical trials within 4 weeks before enrollment; 8. Major surgical procedures unrelated to breast cancer within 4 weeks prior to the first drug administration, or not fully recovered from such procedures; 9. Presence of any active autoimmune disease or history of autoimmune disease with potential for recurrence; 10. Uncontrolled or significant cardiovascular and cerebrovascular diseases; 11. Subjects with known or suspected interstitial pneumonia; 12. Presence of active hepatitis B, hepatitis C, liver cirrhosis; 13. Pregnant or lactating female patients; 14. History of definite neurological or mental disorders, or any other conditions that the investigator believes make the patient unsuitable for participating in this study.